To read full biographies, see below.
The UK board of Oncimmune is:
||– Exec Chairman|
|Professor John Robertson
||– Founder and Chief Scientific Officer|
||– Non Executive|
|Dr Alan Raymond
||– Non Executive|
|Sir Colin Campell
||– Non Executive|
||– Non Executive|
||– Non Executive|
The (USA) LLC board of Oncimmune is:
Additional key personnel within Oncimmune are:
The Science Advisory Board of Oncimmune is:
Geoffrey Hamilton–Fairley, Chairman, is an entrepreneur whose personal commitment to cancer detection can be traced to his father, the first medical oncologist in the United Kingdom.
Professor John Robertson, Chief Scientific Officer and co–founder, is Professor of Surgery at the University of Nottingham and Consultant Surgeon at Nottingham City Hospital. His specialty interest and clinical research have been focused on breast cancer. He has had longstanding laboratory research programmes in the areas of endocrine and growth factor therapies and blood tumor markers. It was in Professor Robertson’s laboratory that the blood test for autoantibodies was developed and which was then transferred into Oncimmune for further development and commercialisation. In addition to being Chief Scientific Officer Professor Robertson also chairs Oncimmune’s Scientific Advisory Board and the Clinical Advisory Groups in breast and lung cancer. Professor Robertson has published over 300 scientific papers in refereed journals, written numerous book chapters and co–edited 3 books. He is the Editor–in–Chief of Breast Cancer Online (www.bco.org), which has the largest breast cancer professional membership of any web–based breast cancer journal. He has advised leading healthcare companies including Astra Zeneca, Novartis, Pfizer, Amgen, Glaxo Smith Kline and Bayer HealthCare. Professor Robertson is an invited speaker at national and international conferences on cancer.
William Jewell, MD, a renowned surgical oncologist, was the first director of the Cancer Center at the University of Kansas Medical Center. During his 35–years career at the medical center, Dr. Jewell pioneered cancer treatments that have since become standard practice in the medical community. Dr. Jewell joined oncimmune (USA) LLC as the U.S. Medical Director.
Caroline Chapman is a PhD biochemist based out of the UK and has provided critical technical leadership since the founding of oncimmune (USA) LLC.
Andrea Murray is a PhD biochemist based out of the UK and has provided critical technical leadership since the founding of oncimmune (USA) LLC.
Laura Peek, a PhD biochemist with expertise in protein characterization and stabilization, was added to oncimmune (USA) LLC’s scientific leadership in the spring of 2007.
Dan Calvo, President and Chief Executive Officer of Oncimmune (USA) LLC, has more than 25 years of progressive experience in the life and health sciences industries with global companies including DuPont, PerkinElmer and Thermo Fisher. More recently, Dan was CEO at 2 private companies, Cellomics and Assay Designs, which were ultimately sold to public companies.
Greg Stanley, Chief Commercial Officer, has over 20 years of executive leadership experience in sales, marketing and commercial operations in the diagnostic industry with Abbott Laboratories, Chiron/Bayer, Radiometer and Roche Diagnostics.
Sudarshan Hebbar, Vice President, MD, is an internist board certified in critical care medicine and nephrology. He practiced critical care medicine and nephrology in Kansas City for 12 years before joining Abbott Diagnostics in 2007 as a senior medical director. He then joined Reata Pharmaceuticals in 2011 as a medical director in Clinical Development. Sudarshan joined Oncimmune (USA) LLC in January 2013 as Vice President, Medical.
Buzz Sztukowski has over 25 years of global health care and life science experience in general management, commercial operations, portfolio management, product development, mergers, acquisitions and integrations. In January 2011 he joined PerkinElmer as the VP & GM Diagnostics Americas. Prior to joining PKI Buzz was Executive Vice President and Chief Commercial Officer for Magellan Biosciences a private $100MM diagnostics company. In 2007 Mr. Sztukowski held the position of Chief Operating Officer and President of International for BioTrove, Inc., which was successfully sold to Life Technologies. Mr. Sztukowski had a nine year tenure at bioMerieux, Inc., a global infectious disease company. There he was Sr. Vice President Global Microbiology Business Area following serving as Senior Vice President North American Commercial Operations. He served as President, Remel Inc., a privately held microbiology company which was sold to Thermo Fisher. During his thirteen tenure at Abbott Diagnostics he held management responsibilities in sales, marketing and product development. Mr. Sztukowski has an MBA from the University of Chicago Booth School of Business and a BS Medical Technology from Fontbonne University.
Charles Morris,MB ChB, MRCP(UK) is Chief Development Officer for ImmunoGen, Inc., a public, development phase biotechnology company. He is a medical oncologist with more than 15 years experience of research and development in the pharmaceutical industry including senior positions at Allos Therapeutics, Cephalon and AstraZeneca.
Professor Gabriel N. Hortobagyi, M.D., F. A. C.Pis currently the Nellie B. Connally Chair in Breast Cancer Research, Director of the Breast Cancer Research program of U. T. M. D. Anderson Cancer Center and Chairman of the Department of Breast Medical Oncology. Dr Hortobagyi has dedicated all his clinical and research efforts to breast cancer since the completion of his fellowship training at U. T. M. D Anderson Hospital, Houston,Texas in 1976. Over the following 20 years he led the clinical development of numerous new cytotoxic and hormonal agents and has had uninterrupted external support for his clinical research group since the late 1970’s. During this time he and his colleagues developed successful curative treatment regimens for locally advanced and inflammatory breast cancer. Dr Hortobagyi was President of the American Society of Clinical Oncology (2006–2007) and has served on the Board of Directors of ASCO. He has also chaired the International Affairs Committee, the Cancer Education Committee(2000–2001, the Nominating Committee (1999–2001) of ASCO and was President of the International Society of Senology (1996–1998) Since 2007Dr Hortobagyi has served as Chair of the Southwest Oncology Group Breast Committee and is currently Chair of the National Surgical Adjutant Breast and Bowel Project Data and Safety Monitoring Committee. He is a corresponding member of the National Academy of Medicine for both Argentina and Mexico and an external member of the National Academy of Sciences, Hungary. Dr Hortobagy is currently serves on the editorial board of 12 journals, has published over 900articles of which over 600 are original full–length articles in peer–reviewed journals, over 140 book chapters and has edited or co–edited 14 books.
Dr Peter Boyle, BSc PhD DSc(Med) DSc FRSE FFPH FRCPS(Glas)FRCP(Edin) FMedSci's appointment as President of the International Prevention Research Institute, Lyon, France follows immediately on his tenure as Director of the International Agency for Research on Cancer(IARC/WHO) from 2004 to 2008 in Lyon, France. From 1991–2004 he had been Director of the Division of Epidemiology and Bio statistics at the Institute of Oncology in Milan, Italy. Prior to this he had had a number of successive appointments with Glasgow University Department of Medicine, the West of Scotland Cancer Surveillance Unit, Harvard School of Public Health and the International Agency for Research on Cancer (IARC/WHO). Professor Boyle is also currently Honorary Professor of Cancer Prevention and Control at Oxford University and Visiting Professor at Glasgow University. Peter Boyle’research interests lie mainly in disease prevention and translational research in its broadest meaning, covering the spectrum from translating cutting–edge scientific discovery into new approaches to cancer treatment to translating information about cancer risk factors into changes in population behaviour. He has published widely on a number of different types of cancer,notably breast, colorectal, pancreas, prostate and oral cavity cancers, as well as on benign urological conditions. He led the EUROCAN PLUS project which developed priorities for coordination of cancer research in Europe and was Editor of the World Cancer Report 2008 which highlighted the growing global cancer crisis. Peter Boyle has previously been Director of the World Health Organisation Collaborating Centre for Chronic Disease Epidemiology and a Member of the European Cancer Advisory Board. In this latter role he worked as scientific ad visor to the European Commission on the European Tobacco Contents Directive which was voted into law in 2003. He was also responsible for the two revisions of the European Code Against Cancer. Peter Boyle has been honoured by the award of the Knight’s Cross of Order of Merit of the Republic of Poland (for contribution to public health in Poland); by election to Fellowship of the Royal Society of Edinburgh; by the award of Honorary Membership in the European Society for Therapeutic Radiology and Oncology (ESTRO), the Hungarian Oncological Association and the Argentine Medical Association; by the award of Fellowship of the Royal College of Physicians and Surgeons of Glasgow; by the award of Fellowship of the Royal College of Physicians of Edinburgh; and by election to the Academy of Medical Sciences of the United Kingdom. In 2006, he was awarded an honorary degree of Doctor of Science by the University of Aberdeen (Scotland, United Kingdom).
John F. Halsey, PhD. In addition to his clinical laboratory director role at Oncimmune, he is a consultant and a scientific director for a number of pharmaceutical and IVD companies. His field of expertise is clinical immunology, immunotoxicology and allergy. He was the founder and CEO of IBT Laboratories, which specialized in molecular and cellular immunology. This laboratory provided unique testing services to major national laboratories and biotherapeutics companies worldwide. Dr. Halsey received his doctoral degree from the Johns Hopkins University and did post–doctoral research at the University of Virginia School of Medicine and the Medical University of South Carolina. While a tenured faculty member in the department of biochemistry and molecular biology at the University of Kansas School of Medicine he directed an NIH funded research program in mucosal immunology and vaccine immunology. During his tenure at the university he was director of graduate studies in biochemistry and served as a panel member on several NIH study sections. Dr. Halsey has 29 years experience in clinical laboratory operations and is an expert in clinical laboratory regulation. Over the past two decades he has developed and launched many new clinical immunology tests. He is the past chair of the Clinical Laboratory Immunology Committee of the American Academy of Allergy Asthma and Immunology. He has served as a consultant to the FDA’s immunology Devices Panel and the Clinical and Laboratory Standards Institute (Formerly NCCLS) and the College of American Pathology CPT Coding Caucus.
Professor Herb Sewell Professor Herb Sewell MB.ChB, BDS,M.Sc, Ph.D, Hon DDS, Hon D.Sc, FRCP, FRCP&S, FRCPath, F.MedSci studied at Birmingham University gaining BDS Hons (1973); following further studies and research in immunology he gained an MSc (1975) and PhD (1978). Subsequently pursued professional training and accreditation in Clinical Immunology and qualified in Medicine (MB ChB in 1983). Appointed Senior Lecturer/Honorary Consultant in Immunology at the University of Aberdeen 1985 and subsequently moved to the University of Nottingham as Professor and Honorary Consultant in Immunology in 1990. In 2002 he was appointed a Pro Vice Chancellor/Vice President at the University of Nottingham (2002–2007). His research interests focus primarily on the Immunology of Allergic Disease and in particular on undulation of the allergic response by the biological properties of allergens and by molecularly engineered antibodies. Additionally,clinical and translational clinical immunology research has been part of his research portfolio for 2 decades. He has published over 120 peer reviewed original papers and reviews well as co–authoring a textbook and many chapters to scholarly textbooks in Medicine and Immunology. He has served on the Editorial Board of Molecular Pathology. He has been a member of the governing Council of the Medical Research Council (MRC UK) (2004–present)and has also been a member of various MRC committees and sub–groups for more than a decade. He was Chair (2007) of the MRC International Review of Human Immunology Research and of Virology Research (2006–08). He has been Chair of various Immunology committees of the UK Royal Colleges of Physician sand of the Royal College of Pathologists. He has been a member of the Heavenly for the UK Research Assessment Exercise (2001). He has served on several Government Department Committees/Advisory Groups dealing with research and development in genetic modification of foods and in Xenotransplantation. He has been a UK Medicine’s Commissioner and a member of Nuffield Council on Bioethics. He has served on several research committees for Cancer Research UK.He was a founding fellow of the UK Academy of Medical Science. Herb has received Honorary Degrees from the University of Birmingham (DDS) and from the University of the West Indies (DSc).
Professor David Kerr Professor David Kerr Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics Professor David Kerr is Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, University of Oxford. He is working with colleagues in Oxford to build a new Institute for Cancer Medicine. He has an international reputation for treatment for and research into colorectal cancer, and he is developing new approaches to cancer treatment which involve gene therapy. Th equality of his work has been recognised by the award of several international prizes and the first NHS Nye–Bevan award for innovation. He has published more than 350 articles in peer–reviewed journals and has contributed to many books on cancer. Professor Kerr has chaired the Advisory Board developing vision for the future of Scotland’s Health Service and produced a 20year plan for the future of the NHS in Scotland, Editor–in–Chief of Annals of Oncology, Europe’s premier medical oncology journal, and is on the editorial broad of several other journals including Nature Clinical Practice Oncology. He was elected Fellow of he Academy of Medical Sciences in2000 and appointed Commander of the British Empire in 2002 and recently elected President of the European Society of Medical Oncology.
Professor Herb Fritsche Professor Herb Fritsche Professor Herbert A. Fritsche Jr. Ph.D. Currently Professor of Laboratory Medicine, U.T.M. D. Anderson Cancer Center, Houston, TX. He has sat on a number of committees of professional societies, been involved with several Scientific Advisory Boards and has numerous honours and awards, some of which are detailed below:Committee Membership Education Committee, Clinical and Diagnostic Immunology Division, American Association for Clinical Chemistry; 1987–1989,1990–1993, 1994–1997, 2008–2011. Committee for Distinguished Scientist Awards, Clinical Ligand Assay Society; 1995–1996 and1996–1997 (Chairman). Abstract Review Committee for National Meeting,American Association Clinical Chemistry; 1995–1998. Expert Panel for Tumor Marker Clinical Practice Guidelines, American Society of Clinical Oncology; 1998–current. Working Group on Tumor Marker Criteria,International Society for Oncodevelopmental Biology and Medicine;1987–1992. Scientific Advisory Board Membership/Consultancies: Hybritech,Inc., San Diego, CA, 1982–1986 Dianon Systems Inc., Stratford, CT,1984–1989 Triton Biosciences Inc., Alameda, CA, 1986–1990 Eastman Kodak, Rochester, NY, 1986–1988 Smith Kline Beecham Clinical Laboratories,Philadelphia, PA, 1989–1999 Mickey Leland National Urban Air Center, Houston, TX, 1992–1995 Horus Therapeutics, Rochester,NY, 1995–1998 Biomira Diagnostics, Toronto, Canada, 1995–1998 Tosoh Medics, Inc., Foster City, CA, 1997–Current diaDexus, Santa Clara, CA,1998–Current Dade Behring Inc., Newark, DE, 1998–Current Breast Cancer On–Line, (www.bco.org), 1999–Current BIOwulf™Genomics, Savannah, GA, 1999–Current International Medical Innovations,Mississauga, Canada, 2000–Current Omnimmune Corp., Houston, TX,2001–Current Ortho Clinical Diagnostics, Raritan, NJ–Current Advanced DNA Diagnostics, Houston, TX, 2001–Current Honors and Awards:Graduate College Research Fellowship Award for 1965–66 and1966–1967 at Texas A&M University, College Station, Texas. U.S. Army Commendation Medal, 1969. Texas Section, American Association for Clinical Chemistry, Outstanding Clinical Chemist Award for 1979. American Association for Clinical Chemistry, Presidential Citation for 1981. American Association For Clinical Chemistry, 1992 Annual National Award for Outstanding Contributions in Education. Dean’s Excellence Award for1993–1994, Graduate School of Biomedical Sciences, University of Texas Health Science Center. National Academy of Clinical Biochemistry, Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry, 1997. Elected to Fellow in the Academy of Clinical Biochemistry(FACB) National Academy of Clinical Biochemistry, 1997. Elected to President,Clinical Ligand Assay Society for 1999. American Association for Clinical Chemistry, Outstanding Speaker Awards for 1995 and 1997. Distinguished Scientist Award for 1999, Clinical Ligand Assay Society. 2006 Morton K.Schwartz Award for Research Accomplishments in Cancer Diagnostics. 2009 Carl Jolliff Lifetime Achievement Award for contributions in clinical and diagnostic immunology. He is an author of over 200 peer reviewed research publications.
George H. Parsons, PhD Dr. Parsons is the Managing Director and founder of Parsons Group LLC, an in vitro diagnostics consulting company,serving clients in the U.S. and Europe He received his B.A. in Chemistry (magna cum laude) from Boston University and his M.A. and Ph.D. in Physical Organic Chemistry from Brandeis University. After teaching for 2 years at Boston University, he entered the business world as a development chemist for Clinical Assays, Inc in Cambridge, MA. Within 2 years he was made Technical Director and managed a team of 40 professionals developing state of the art immunoassays.Leaving Clinical Assays, he joined the founding management team of Medical& Scientific Designs in Rockland, MA where he managed a team developing assays in a novel format for one of the first computer controlled immunoassay instruments. Seeking experience in a new area, he joined Gene–TrakSystems and helped develop DNA probe assays for various food pathogens. There he became General Manager of the Food Diagnostics Division and had overall P&L responsibility for the operation. Returning to his R&D roots, he did an R&D turnaround at T–Cell Diagnostics with novel cell surface marker immunoassays as VP of R&D. He then joined PerSeptive Biosystems to explore immunoassays on HPCL, Capillary Electrophoresis and Mass Spectrometry.At Chiron Diagnostics he managed groups of 40–80 scientists developing magnetic particle chemiluminescent assays on automated random access platforms.As Director of Business Development for Future Diagnostics, B.V. he was responsible for marketing contract assay development services to companies ranging from well established multinationals to startups. In January 2008, he launched his own consulting company Parsons Group LLC. Dr. Parsons is the inventor or co–inventor on 11 allowed U.S. patents, has authored many peer reviewed articles and book chapters on immunoassay. In the 35 years he has been in the industry, Dr. Parsons and his groups have introduced more than 85assays to the market. He has also been the Chair of the Oak Ridge meeting sponsored by AACC and has been active in local AACC Section activities as Program Chair, Chair and currently Membership Chair.
Professor Bill Wood Professor William C. Wood, M.D.,F.A.C.S., F.R.C.S.,Eng.(Hon.), F.R.C.S.,Glasg. is currently the Distinguished Joseph Brown Whitehead Professor of Surgery at Emory University School of Medicine. He was Chief of Surgical Oncology and Clinical Director of the MGH Cancer Center at Harvard before becoming Chairman of the Department of Surgery at Emory (1990–2009) and Clinical Director of the Winship Cancer Center(1991–2000). He has devoted his research efforts to oncology, first in the immunology of autoantibodies to tumor associated antigens, then in clinical trials of multi-modality treatment of breast cancer. He has served as Chair of the Cancer and Leukemia Group B Breast Committee (1979–1990), as Chair of the Eastern Cooperative Oncology Group Breast Committee (1991–1997), as Chair of the NCI Breast Intergroup(1991–2008), as Co–Chair of the Early Breast Cancer Trialists’ Collaborative Group (Oxford)(1995–2005), and currently as Co–Chair of the NCI Breast Cancer Steering Committee. He chairs the (Neo)ALTTO Independent Data Monitoring Committee. He has been a Governor of the American College of Surgeons, a Director of the American Society of Clinical Oncology, member of the Board of Scientific Advisers of the National Cancer Institute, President of the Society Of Surgical Oncology, of the Southeastern Surgical Congress, of the Georgia Surgical Association and the Atlanta Surgical Association, and is currently President of the Southern Surgical Association. He isEditor–in–Chief of Oncology, and has written over 260full–length scientific articles, over 35 book chapters, and has edited orco–edited 7 books.
Daniel Fleming Hayes, M.D.Daniel Fleming Hayes, M.D. is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, where he is the Stuart B. PadnosProfessor of Breast Cancer Research. Over the last two decades, Dr.Hayes’ professional training and career have been directed towardbridging the gap between laboratory and clinical research. He received abachelor’s degree (1974) in biology and a master’s degree (1977) inbiochemistry at Indiana University. He received his M.D. from the IndianaUniversity School of Medicine in 1979, followed by a residency in internalmedicine at the University of Texas Health Science Center at Dallas, Texas(Parkland Memorial and affiliated hospitals). He served a fellowship in medicaloncology from 1982–1985 at Harvard’s Dana Farber Cancer Institutein Boston, where he subsequently distinguished himself on the faculty inregards to breast cancer research and care. In 1992, he assumed the role as theMedical Director of the Breast Evaluation Center at DFCI. He held that titleuntil 1996, when he moved to Georgetown University and spent the succeedingfive years establishing an enormously successful collaboration with Dr. Marc E.Lippman. In 2001, both Drs. Lippman and Hayes joined the University of MichiganCancer Center to continue their fruitful relationship in the context of theexisting translational science. Dr. Hayes has been influential in both clinicaland laboratory studies of the diagnosis and treatment of breast cancer. Dr.Hayes and colleagues published the first reports concerning the development of the CA15–3 blood test, which is currently used world–wide toevaluate patients with breast cancer. He has become an internationallyrecognized leader in the use of this and other tumor markers, such asHER–2, circulating tumor cells and pharmacogenomics. Recently, he and hiscolleagues have reported ground breaking results regarding circulating tumorcells in metastatic breast cancer as well as the pharmacogenomics of tamoxifen.He is widely considered to be an expert in the field of clinical research ofbreast cancer, especially in regards to new hormonal and chemotherapeutictreatments. He lectures and publishes extensively regarding the management ofpatients with breast cancer. In 2007, he was awarded the American Society ofClinical Oncology’s Gianni Bonadonna Breast Cancer Award. Reflecting hisexpertise, Dr. Hayes has been Chair of the Solid Tumor Correlative SciencesCommittee of the Cancer and Leukemia Group B (CALGB), one of the leadingfederally–funded multi–institutional cooperative groups thatperform definitive clinical research in cancer care and he is now Chair of theBreast Cancer Translational Medicine Committee of the Southwest Oncology Group(SWOG). He is Chair of the Correlative Sciences Committee of the U.S. BreastCancer Intergroup, and he co–chairs the Expert Panel for Tumor MarkerPractice Guidelines for the American Society of Clinical Oncology. He serves onthe editorial boards of several leading cancer journals. Dr. Hayes lives in AnnArbor, Michigan with his wife, Jane.